The Campaign Against Pharma Companies Creates New Level of Uncertainty for all Patent Attorneys re Duty of Disclosure and Inquiry

“We agree with the USPTO, FDA and White House that inconsistent statements are unacceptable. Likewise, inconsistent laws and policies (e.g., the wording of Section 101 versus SCOTUS law; the wording of Section 103 versus double patenting law; and now the…








